Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedJun 08, 2026
DataAggregated Company Financials
Companies548
  • 7D-1.7%
  • 3M-5.2%
  • 1Y26.1%
  • YTD-0.04%

Over the last 7 days, the Biotech industry has dropped 1.7%, driven by declines in Gilead Sciences and Revolution Medicines of 2.3% and 9.3%, respectively. This takes the industry's 12 month performance to a gain of 26%. Earnings are forecast to grow by 25% annually.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 09 Jun 2026US$1.3tUS$170.0b-US$12,160,280,783.8216.6x-104.3x7.5x
Thu, 07 May 2026US$1.3tUS$169.1b-US$11,573,182,334.7717.8x-110.9x7.6x
Sat, 04 Apr 2026US$1.3tUS$166.1b-US$11,599,925,313.8416x-111.1x7.8x
Mon, 02 Mar 2026US$1.4tUS$169.4b-US$12,634,834,488.1021.8x-106.9x8x
Wed, 28 Jan 2026US$1.3tUS$163.6b-US$15,072,952,042.0320.1x-84.5x7.8x
Fri, 26 Dec 2025US$1.3tUS$163.6b-US$15,777,655,356.5322.2x-79.3x7.7x
Sun, 23 Nov 2025US$1.2tUS$163.8b-US$16,230,750,145.9818.2x-74.2x7.4x
Tue, 21 Oct 2025US$1.2tUS$163.4b-US$18,381,279,402.2916.2x-64.4x7.2x
Thu, 18 Sep 2025US$1.1tUS$163.5b-US$18,382,703,631.6416.1x-57.9x6.5x
Sat, 16 Aug 2025US$1.1tUS$163.6b-US$18,749,403,227.2315.6x-56.7x6.5x
Mon, 14 Jul 2025US$974.6bUS$155.8b-US$23,414,756,764.1818.1x-41.6x6.3x
Wed, 11 Jun 2025US$956.0bUS$155.9b-US$23,940,308,496.7317x-39.9x6.1x
Fri, 09 May 2025US$890.8bUS$155.2b-US$25,508,884,067.7618.2x-34.9x5.7x
Sun, 06 Apr 2025US$735.9bUS$118.6b-US$37,018,260,571.7320.1x-19.9x6.2x
Tue, 04 Mar 2025US$851.9bUS$119.0b-US$37,239,165,117.4618.7x-22.9x7.2x
Thu, 30 Jan 2025US$991.6bUS$149.5b-US$26,328,617,325.6517.4x-37.7x6.6x
Sat, 28 Dec 2024US$987.9bUS$149.9b-US$26,371,086,316.3016.2x-37.5x6.6x
Mon, 25 Nov 2024US$1.0tUS$150.0b-US$26,558,578,256.4416.6x-38.3x6.8x
Wed, 23 Oct 2024US$895.9bUS$113.1b-US$36,020,987,135.8021.4x-24.9x7.9x
Fri, 20 Sep 2024US$919.7bUS$113.2b-US$35,956,842,944.7222.1x-25.6x8.1x
Sun, 18 Aug 2024US$883.1bUS$113.2b-US$35,819,260,655.8322.3x-24.7x7.8x
Tue, 16 Jul 2024US$1.2tUS$164.5b-US$28,103,794,830.8229x-42.5x7.3x
Thu, 13 Jun 2024US$1.2tUS$164.5b-US$28,092,824,135.2828x-41.1x7x
Sat, 11 May 2024US$1.1tUS$164.6b-US$26,942,623,519.8323.3x-41.5x6.8x
Mon, 08 Apr 2024US$1.1tUS$164.4b-US$23,377,298,863.0321.3x-48.3x6.9x
Wed, 06 Mar 2024US$1.2tUS$167.9b-US$21,336,854,000.7816.1x-55.9x7.1x
Fri, 02 Feb 2024US$1.4tUS$204.7b-US$22,768,331,138.0019x-63.6x7.1x
Sun, 31 Dec 2023US$1.4tUS$204.9b-US$22,199,644,413.0019.8x-62.6x6.8x
Tue, 28 Nov 2023US$1.2tUS$204.8b-US$22,010,873,467.0018.7x-55.7x6x
Thu, 26 Oct 2023US$1.2tUS$207.4b-US$13,064,474,784.0016.4x-92.7x5.8x
Sat, 23 Sep 2023US$1.3tUS$207.5b-US$12,879,348,159.0017.1x-97.9x6.1x
Mon, 21 Aug 2023US$1.3tUS$207.6b-US$12,372,676,716.0017.6x-102.2x6.1x
Wed, 19 Jul 2023US$1.1tUS$186.7b-US$15,964,743,132.0012.8x-71.3x6.1x
Fri, 16 Jun 2023US$1.2tUS$186.3b-US$15,880,859,492.0012.2x-72.5x6.2x
Price to Earnings Ratio

-72.5x


Total Market Cap: US$1.2tTotal Earnings: -US$15,880,859,492.00Total Revenue: US$186.3bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average -58.2x202420252026
Current Industry PE
  • Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 6.9x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 3.0% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-2.49%
Healthcare1.76%
Biotech-1.65%
Biotech-1.65%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ABBV AbbVieUS$223.074.8%
+US$17.9b		17.9%PE109.6x
AMGN AmgenUS$345.665.0%
+US$8.9b		19.2%PE23.9x
VRTX Vertex PharmaceuticalsUS$442.961.0%
+US$1.2b		-0.7%PE25.9x
TNGX Tango TherapeuticsUS$30.9333.9%
+US$1.1b		643.5%PS78.5x
LEGN Legend BiotechUS$31.5223.6%
+US$1.1b		-9.4%PS5.1x

Latest News

TNGX
US$30.93
Tango Therapeutics
7D
33.9%
1Y
643.5%
MRNA
US$47.60
Moderna
7D
3.3%
1Y
69.2%
REGN
US$611.34
Regeneron Pharmaceuticals
7D
1.8%
1Y
18.1%
GILD
US$128.10
Gilead Sciences
7D
-2.3%
1Y
13.4%
RVMD
US$148.49
Revolution Medicines
7D
-9.3%
1Y
265.9%
SMMT
US$14.11
Summit Therapeutics
7D
-10.2%
1Y
-34.6%
LEGN
US$31.52
Legend Biotech
7D
23.6%
1Y
-9.4%
PRAX
US$253.25
Praxis Precision Medicines
7D
-24.4%
1Y
469.0%
ONC
US$270.80
BeOne Medicines
7D
-3.2%
1Y
2.7%
Narrative Update • Jun 06

ONC: Hematology Leadership And Solid Tumor Pipeline Will Drive Future Upside

Analysts have nudged the fair value estimate for BeOne Medicines to about $337 per share, citing higher price targets from several firms as they factor in the recent accelerated approval of sonrotoclax and updated views on the company’s solid tumor pipeline. Analyst Commentary Recent research on BeOne Medicines reflects a mixed set of views.
ABBV
US$223.07
AbbVie
7D
4.8%
1Y
17.9%
Narrative Update • Jun 06

ABBV: Future Returns Will Depend On Expanding Immunology And IBD Pipeline Execution

AbbVie’s updated analyst price target edges higher to $253.55 from $249.43 as analysts factor in slightly higher profit margin assumptions, modestly lower revenue growth expectations, a reduced discount rate, and a somewhat lower future P/E multiple, with recent research highlighting the depth of the inflammatory bowel disease pipeline and broader R&D optionality. Analyst Commentary Recent Street research on AbbVie shows a mix of optimism and caution, with multiple price target revisions clustered within a relatively tight range and commentary that keeps attention on the inflammatory bowel disease pipeline and broader R&D portfolio.
VRTX
US$442.96
Vertex Pharmaceuticals
7D
1.0%
1Y
-0.7%
AMGN
US$345.66
Amgen
7D
5.0%
1Y
19.2%
CELC
US$87.43
Celcuity
7D
-28.9%
1Y
577.2%
INCY
US$100.64
Incyte
7D
5.3%
1Y
44.0%
INSM
US$94.17
Insmed
7D
-11.2%
1Y
33.2%
Narrative Update • Jun 02

INSM: 2026 Respiratory Launch Execution Will Drive Bronchiectasis Leadership Debate

Analysts have trimmed their average price target on Insmed to about $200 from $212.50, reflecting updated Q1 models that factor in recent competitive developments and refreshed Brinsupri expectations, while still largely maintaining constructive views on the stock. Analyst Commentary Street research around Insmed has been active, with multiple firms adjusting price targets and ratings following Q1 results, clinical updates and early feedback on Brinsupri.
BNTX
US$85.50
BioNTech
7D
-6.8%
1Y
-21.5%
Narrative Update • Jun 01

BNTX: Leadership Upheaval And Oncology Trial Risks Will Pressure Expectations

Analysts have modestly reduced the fair value estimate for BioNTech to about $82 per share, reflecting slightly lower long term assumptions. These are partly offset by higher projected profit margins and renewed interest in the oncology pipeline following recent price target changes and an upgrade from Neutral to Buy at one large bank.